Navigation Links
C. Difficile Tox A/B II

ProductsC. Difficile Tox A/B II
Company Inverness Medical Innovations
Item C. Difficile Tox A/B II
Features 
  • Detects both A+ and A-/B+ strains
  • Assay is performed within 30 minutes
  • No gray zone eliminates equivocal results
  • Excellent correlation to tissue culture
  • Results can be interpreted using manual or automated methods
Description The C. Difficile Tox A/B II is a second-generation rapid ELISA for the detection of Clostridium difficile toxins A and B in fecal specimens. The test utilizes highly specific antibodies and produces highly sensitive results detecting not only the more common toxin A+ samples, but also samples that are toxin A-/B+. It's easy to perform, produces no indeterminates and provides results in one hour or less. The relative sensitivity and specificity of the test are 92.2% and 100%, respectively, when compared to tissue culture.
Info Inverness Medical Innovations
Customer Service: 800-257-9525
Web site: http://www.invernessmedical.com/

Related medicine products :

1. Clostridium Difficile Toxin A RAPYDTEST®
2. Bartels® C. Difficile Toxin A Antigen EIA with Controls
3. Difficile Tox A/B II with Fecal-Quik-Prep
... Many special order products are offered ... extra long lengths. The modular instruments may ... other options such as ratchets, insulation and ... from Mediflex stock. Customer specifications may affect ...
... products are offered as 1-piece or modular, ... modular instruments may be customized with handles ... ratchets, insulation and flush ports. Many standard ... specifications may affect delivery times. , ...
... special order products are offered as 1-piece ... lengths. The modular instruments may be customized ... such as ratchets, insulation and flush ports. ... stock. Customer specifications may affect delivery times. ...
... products are offered as 1-piece or modular, ... modular instruments may be customized with handles ... ratchets, insulation and flush ports. Many standard ... specifications may affect delivery times. , ...
Medicine Products:
(Date:1/19/2017)... ... ... WhoHaha , a digital media company dedicated to creating and delivering female-centric, comedic content, ... series that uses humor to highlight ways to improve heart health and overall well-being. ... movement, which is designed to inspire all Americans to make small changes that add ...
(Date:1/19/2017)... ... January 19, 2017 , ... Dr. Andrew Lian-Jie ... fellowship trained Mohs and cosmetic surgeon. After extensive dermatology research training at the ... internship in internal medicine at the Emory University and dermatology training at the ...
(Date:1/19/2017)... ... January 19, 2017 , ... ... for patients with sleep apnea and TMJ disorders. These conditions are quite common ... Dr. Rassouli provides personalized care to reduce the risk of these consequences and ...
(Date:1/19/2017)... (PRWEB) , ... January 19, 2017 , ... ... asset protection and financial planning services to communities throughout eastern Georgia, is embarking ... against heart disease. , Heart disease kills more Americans every year than anything ...
(Date:1/19/2017)... ... January 19, 2017 , ... Creative ... Create Real Impact contest from Impact Teen Drivers and California Casualty. Entries from ... , Educational grants totaling $15,000 will be awarded for the best peer-to-peer ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... -- Incretin Mimetics/GLP-1 Agonists, SNDRIs, Lipase Inhibitors, Serotonin Receptor ... global anti-obesity drugs market is expected to grow at a ... and CAGR of 38.7% in the second half of the forecast ... 32.8% from 2016 to 2027. The market is estimated at $1,058 ... 2027. ...
(Date:1/19/2017)... 19, 2017  Sensus Healthcare, Inc. (NASDAQ: ... in the treatment of non-melanoma skin cancers and ... radiation therapy, today announced that it will report ... results on Thursday, February 2, 2017 after the market ... conference call with the investment community on Thursday, February ...
(Date:1/19/2017)... New Review of Safinamide ... Symptoms and Motor Complications in Mid- to Late-stage ... ... C Warren Olanow ... 2): 2-15, http://www.touchneurology.com/articles/safinamide-new-therapeutic-option-address-motor-symptoms-and-motor-complications-mid-late Published ...
Breaking Medicine Technology: